Cost-effectiveness Analysis of Three Chemotherapy Regimens for Metastatic Colorectal Cancer
10.6039/j.issn.1001-0408.2015.32.01
- VernacularTitle:3种化疗方案治疗转移性结直肠癌的成本-效果分析
- Author:
Yan CHEN
;
Guoming CHEN
;
Ying ZHAN
;
Hua SHAO
- Publication Type:Journal Article
- Keywords:
Metastatic colorectal cancer;
Chemotherapy regimen;
Oxaliplatin;
Calcium folinate;
5-fluorouracil;
Irinotecan;
Capecitabine;
Cost-effectiveness analysis
- From:
China Pharmacy
2015;(32):4465-4467
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate clinical efficacy of oxaliplatin+calcium folinate+5-fluorouracil(mFOLFOX6),oxalipl-atin+capecitabine(CapeOX),irinotecan+calcium folinate+5-fluorouracil(FOLFIRI)for metastatic colorectal cancer,and to conduct cost-effectiveness analysis. METHODS:48 patients with colorectal cancer were divided into mFOLFOX6 group(30 cases),Cape-OX group(8 cases)and FOLFIRI group(10 cases). Clinical efficacy and ADR of 3 groups were analyzed,and cost-effectiveness analysis was also conducted. RESULTS:Clinical effective rates of mFOLFOX6 group,CapeOX group and FOLFIRI group were 96.67%,87.50% and 80.00%,respectively,the mFOLFX6 group was significantly higher than the other 2 groups,with statistical significance(P<0.05). mFOLFOX6 group had high incidence of gastrointestinal side effects (70.00%). FOLFIRI group had high incidence of myelosuppression (70.00%). CapeOX and mFOLFOX6 group suffered from liver injury possibly,without statistical significance (P>0.05). The C/E of mFOLFOX6 group,CapeOX group and FOLFIRI group were 11 950,15 674 and 18 397 re-spectively,to which results of sensitivity analysis were same. CONCLUSIONS:The cost-effectiveness of mFOLFOX6 regimen is superior to CapeOX and FOLFIRI regimen in the treatment of metastatic colorectal cancer,but it has the high incidence of gastroin-testinal side effects.
